Published online May 14, 2016. doi: 10.3748/wjg.v22.i18.4576
Peer-review started: December 25, 2015
First decision: January 28, 2016
Revised: February 11, 2016
Accepted: March 1, 2016
Article in press: March 2, 2016
Published online: May 14, 2016
Processing time: 131 Days and 8.8 Hours
AIM: To explore the correlation between Helicobacter pylori (H. pylori)-associated gastric diseases and colorectal neoplasia.
METHODS: Patients included in this study underwent a colonoscopy and esophago-gastro-duodenoscopy (EGD) along with histopathological measurement between March 2012 and March 2015 at Qi-Lu Hospital of Shandong University, who also had results of H. pylori detection. A total of 233 cases were selected. Demographic data, H. pylori infection status (including results of rapid urease tests and gastric mucosa pathological examinations) and histopathological examination results of gastric and colorectal mucosa were gathered and analyzed. The statistical analysis focused on the prevalence of colorectal neoplasms among patients with various histopathological categories of the stomach. ORs and their 95%CI were calculated to describe the strengths of the associations.
RESULTS: The incidence rates of colorectal adenoma without high-grade intraepithelial neoplasia (HGIEN) (OR = 2.400, 95%CI: 0.969-5.941), adenoma with HGIEN (5.333, 1.025-27.758) and adenocarcinoma (1.455, 0.382-5.543) were all higher for patients with H. pylori-associated gastritis than for those in the control group. The incidence rate of colorectal adenoma with HGIEN (3.218, 0.767-13.509) was higher in patients with intestinal metaplasia than in the control group, while the incidence rates of adenoma without HGIEN (0.874, 0.414-1.845) and adenocarcinoma (0.376, 0.096-1.470) were lower in the intestinal metaplasia group than in the control group. The incidence rate of colorectal adenoma without HGIEN (3.111, 1.248-7.753) was significantly higher in the gastric intraepithelial neoplasia group than in the control group, while the rates of adenoma with HGIEN (1.481, 0.138-15.941) and adenocarcinoma (2.020, 0.561-7.272) were higher in the gastric intraepithelial neoplasia group. Incidence rates of colorectal adenoma without HGIEN (1.067, 0.264-4.314), adenoma with HGIEN (2.667, 0.231-30.800) and adenocarcinoma (2.182, 0.450-10.585) were all higher in the gastric adenocarcinoma group than in the control group.
CONCLUSION: H. pylori infection as well as H. pylori-associated gastric diseases are risk factors for colorectal neoplasia.
Core tip: Few studies have investigated the relationship between Helicobacter pylori (H. pylori)-associated gastric diseases and colorectal neoplasia. In particular, no such research on the Chinese population has been reported so far. To explore this correlation in the Chinese population, demographic data, H. pylori infection status and histopathological data of gastric and colorectal mucosa of 233 Chinese patients were gathered and analyzed. The results demonstrated that H. pylori-associated gastric diseases might increase the risk of colorectal neoplasia regardless of the number, size and location of the neoplasm. Therefore, we can assume that H. pylori-associated gastric diseases are potential risk factors for colorectal neoplasia in the Chinese population.
- Citation: Qing Y, Wang M, Lin YM, Wu D, Zhu JY, Gao L, Liu YY, Yin TF. Correlation between Helicobacter pylori-associated gastric diseases and colorectal neoplasia. World J Gastroenterol 2016; 22(18): 4576-4584
- URL: https://www.wjgnet.com/1007-9327/full/v22/i18/4576.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i18.4576
Colorectal cancer (CRC) is one of the most common malignancies worldwide. In China, the incidence and mortality rates of CRC have increased in recent years[1]. Due to the lack of specific clinical manifestations, the early diagnosis of CRC is relatively difficult, leading to the poor prognosis. Therefore, it is of great importance to elucidate the pathogenesis and risk factors of CRC, and develop relevant prevention and early detection strategies. During the development of CRC, the mucosa will progress from normal mucosa to adenoma first, and then to adenocarcinoma. This process provides the chance for early detection and intervention of CRC, and colorectal adenoma is considered the most important precancerous lesion for CRC. These two diseases, colorectal adenoma and CRC, are collectively called colorectal neoplasia.
It is believed that the development of colorectal neoplasia is associated with Helicobacter pylori (H. pylori) infection[2,3], although the pathophysiological mechanism underlying the correlation remains unclear. Most scholars believed that H. pylori might induce colorectal neoplasia by regulating the expression of serum gastrin[4,5]. Persistent H. pylori infection can lead to various gastric diseases, including gastritis, gastric intestinal metaplasia, gastric intraepithelial neoplasia and gastric adenocarcinoma. Chronic atrophic gastritis (CAG), which may progress to intestinal metaplasia, intraepithelial neoplasia and adenocarcinoma, can lead to decreased gastric acid secretion by extensive glandular atrophy. Serum gastrin level will increase accordingly through the negative feedback regulation, which shall then act as a trophic factor for colorectal mucosa. Therefore, different kinds of H. pylori-associated gastric diseases may be correlated with different levels of colorectal neoplasia depending on the serum gastrin level. Although several previous studies concluded that H. pylori seropositivity was associated with colorectal neoplasia[4,6-8], few have investigated the relationship between H. pylori-associated gastric diseases and colorectal neoplasia. In particular, no such research on the Chinese population has been reported so far.
In this research, we carried out a retrospective analysis of a database of 60501 Chinese patients who underwent esophago-gastro-duodenoscopy (EGD) and/or colonoscopy, trying to explore the possible correlation between H. pylori-associated gastric diseases and colorectal neoplasia.
A total of 60501 Chinese patients underwent EGD and/or colonoscopy between March 2012 and March 2015 at Qi-Lu Hospital of Shandong University. Out of those 60501 patients, those who had both EGD and complete colonoscopy (including the colonoscopy of the entire large intestine) were selected in the study. Histopathological results of gastric mucosa and colorectal mucosa as well as the results of H. pylori measurement were taken for all subjects. None of those patients in this study had a previous history of inflammatory bowel diseases (IBS), hereditary non-polyposis colorectal cancer (HNPCC) or familial adenomatous polyposis (FAP). None of them received H. pylori eradication therapy, gastrointestinal surgery, radiotherapy, chemotherapy, or other biotherapies targeting the cancer. No patients had a long-term drug use history. Based on the aforementioned criteria, a total of 233 patients were chosen.
Demographic data, H. pylori infection status and histopathological results of gastric and colorectal mucosa were collected for all subjects. H. pylori infection status was determined by rapid urease test (RUT) and histopathological examination of gastric mucosa. H. pylori positivity was defined as results from one or both examinations were positive. EGD and colonoscopy were performed with EG-2990i electronic gastroscopes and EC-3890Fi electronic colonoscopes (Pentax, Tokyo, Japan), respectively. The location, number, and size of polyps were recorded during the colonoscopy.
All data were from existing records and personal identities were removed before the data were used in this study. Therefore, there was no need to obtain informed consent from patients.
Among the 233 patients, 159 (68.2%) had gastric antrum biopsies, 59 (25.3%) had gastric body and fundus biopsies, 29 (12.4%) had cardia biopsies, and 20 (8.6%) had multiple-site biopsies. The diagnostic criteria of the gastric biopsies were set according to the updated Sydney system[9]. Based on the sample size of this study, patients were divided into four groups according to their histopathological results of gastric mucosa: chronic gastritis group (including chronic non-atrophic gastritis and CAG), gastric intestinal metaplasia group, gastric intraepithelial neoplasia group and gastric adenocarcinoma group.
The following four histopathological categories were used for the colorectal mucosa: inflammation or non-adenomatous polyps (including hyperplastic polyps, inflammatory polyps, etc.), adenoma (including tubular adenoma, tubulovillous adenoma and villous adenoma) without high-grade intraepithelial neoplasia (HGIEN), adenoma with HGIEN and colorectal adenocarcinoma. Polyps were grouped based on their location such as rectum (including rectosigmoid junction), sigmoid colon, descending colon, transverse colon and ascending colon (including ileocecal junction). Polyps were also grouped based on the number: 1-3, 4-9 and > 10. Adenomas were grouped based on their size: 0-9 mm, 10-19 mm and > 20 mm.
The degree of correlations between H. pylori-associated gastric diseases and colorectal neoplasia was measured by ORs and their 95%CIs. χ2 test was applied to calculate P-values. When the expected frequency was less than 5, Fisher’s exact test was used to calculate P-values. P-values less than 0.05 were considered statistically significant. All statistical analyses were performed using Excel 2013 (Microsoft, Redmond, WA, United States) and SPSS 20.0 (SPSS, Chicago, IL, United States). The statistical methods of this study were reviewed by Dr. Jing Liu from Department of Epidemiology and Biostatistics, School of Public Health, Shandong University.
All 233 Chinese patients were between 16 and 89 years old, with the mean age at 56.85 ± 12.38 years. Of the 233 patients, 70.4% were males (164 patients), aged between 16 and 83 years with the mean at 56.69 ± 12.06 years, and 29.6% were females (69 patients), aged between 16 and 89 years with the mean at 57.22 ± 13.19 years. The clinical indications for EGD and colonoscopy are listed in Table 1.
Indication for EGD and colonoscopy | EGD | Colonoscopy |
Abdominal discomfort | 78 (33.5) | 65 (27.9) |
Diarrhea | 26 (11.2) | 47 (20.2) |
Hematochezia | 12 (5.2) | 34 (14.6) |
Weight loss | 10 (4.3) | 13 (5.6) |
Others | 58 (24.9) | 39 (16.7) |
Dyspepsia | 33 (14.2) | |
Reflux esophagitis | 42 (18.0) | |
Emesis | 21 (9.0) | |
Colorectal cancer screening | 25 (10.7) | |
Polypectomy following-up | 24 (10.3) |
H. pylori-associated gastritis is a gastric disease while the histopathological type was chronic gastritis (including chronic non-atrophic gastritis and CAG) with H. pylori infection (the infection status was determined by RUT and histopathological examination). Because no patient included in this research had completely normal histopathological results of gastric mucosa, patients with chronic gastritis and negative H. pylori were used as control group 1 in this research. For the same reason, patients with colorectal inflammation or non-adenomatous polyps were used as control group 2.
As shown in Table 2, compared to the patients in the control group 1, patients with H. pylori-associated gastritis were younger and had a higher rate of males. The incidence rates of colorectal adenoma without HGIEN, colorectal adenoma with HGIEN or colorectal adenocarcinoma were higher in the H. pylori-associated gastritis group than in the control group 1. The incidence rate of H. pylori-associated gastritis was much lower for patients in the control group 2 than for those in the other three groups (the colorectal adenoma group without HGIEN, the colorectal adenoma group with HGIEN and the colorectal adenocarcinoma group). The correlation between H. pylori-associated gastritis and colorectal neoplasms was the highest when the number of polyps was between 4 and 9 (OR = 2.857, 95%CI: 0.983-8.306, P = 0.049). In addition, the association of H. pylori-associated gastritis with colorectal neoplasms was independent of colorectal neoplasms size, with OR values greater than 1. The association was highest when the polyps were located at the descending colon (OR = 2.737, 95%CI: 1.018-7.357, P = 0.043).
Parameter | Total number of patients (n = 233) | H. pylori-associated gastritis | Control group 1 | OR | 95%CI | P value |
Age | 56.85 | 52.72 ± 11.37 | 56.42 ± 14.90 | - | - | - |
Male | 164 | 27 (16.5) | 48 (29.3) | 1.000 | - | - |
Female | 69 | 9 (13.0) | 36 (52.2) | 0.444 | 0.186-1.060 | 0.064 |
Control group 2 | 95 | 10 (10.5) | 40 (42.1) | 1.000 | - | - |
Adenoma without HGIEN | 92 | 18 (19.6) | 30 (32.6) | 2.400 | 0.969-5.941 | 0.055 |
Adenoma with HGIEN | 16 | 4 (25.0) | 3 (18.8) | 5.333 | 1.025-27.758 | 0.054 |
Adenocarcinoma | 27 | 4 (14.8) | 11 (40.7) | 1.455 | 0.382-5.543 | 0.721 |
Polyp number | ||||||
1-3 | 106 | 16 (15.1) | 36 (34.0) | 1.778 | 0.716-4.414 | 0.212 |
4-9 | 46 | 10 (21.7) | 14 (30.4) | 2.857 | 0.983-8.306 | 0.049 |
10+ | 20 | 3 (15.0) | 9 (45.0) | 1.333 | 0.304-5.852 | 0.703 |
Adenoma size (mm) | ||||||
0-9 | 82 | 15 (18.3) | 25 (30.5) | 2.400 | 0.934-6.165 | 0.066 |
10-19 | 30 | 5 (16.7) | 9 (30.0) | 2.222 | 0.609-8.108 | 0.286 |
20+ | 16 | 4 (25.0) | 7 (43.8) | 2.286 | 0.558-9.366 | 0.256 |
Polyp location | ||||||
Rectum | 79 | 14 (17.7) | 33 (41.8) | 1.697 | 0.667-4.315 | 0.264 |
Sigmoid colon | 77 | 12 (15.6) | 22 (28.6) | 2.182 | 0.813-5.856 | 0.118 |
Descending colon | 64 | 13 (20.3) | 19 (29.7) | 2.737 | 1.018-7.357 | 0.043 |
Transverse colon | 55 | 11 (20.0) | 17 (30.9) | 2.588 | 0.927-7.230 | 0.065 |
Ascending colon | 57 | 11 (19.3) | 18 (31.6) | 2.444 | 0.880-6.787 | 0.082 |
There were more old people and males in the gastric intestinal metaplasia group than in the control group 1 (Table 3). The incidence rate of colorectal adenoma with HGIEN was higher in the gastric intestinal metaplasia group than in the control group 1, while the incidence rates of colorectal adenoma without HGIEN and colorectal adenocarcinoma were lower in the gastric intestinal metaplasia group. The inconsistency may be due to the small sample size, as there were only three patients with both gastric intestinal metaplasia and colorectal adenocarcinoma. Therefore, each individual case had a big impact on the OR value, leading to poor reliability of the final conclusion.
Parameter | Total number of patients (n = 233) | Gastric intestinal metaplasia | Control group 1 | OR | 95%CI | P value |
Age | 56.85 | 58.39 ± 7.34 | 56.42 ± 14.90 | - | - | - |
Male | 164 | 44 (26.8) | 48 (29.3) | 1.000 | - | - |
Female | 69 | 15 (21.7) | 36 (52.2) | 0.455 | 0.219-0.941 | 0.032 |
Control group 2 | 95 | 29 (30.5) | 40 (42.1) | 1.000 | - | - |
Adenoma without HGIEN | 92 | 19 (20.7) | 30 (32.6) | 0.874 | 0.414-1.845 | 0.723 |
Adenoma with HGIEN | 16 | 7 (43.8) | 3 (18.8) | 3.218 | 0.767-13.509 | 0.172 |
Adenocarcinoma | 27 | 3 (11.1) | 11 (40.7) | 0.376 | 0.096-1.470 | 0.149 |
Polyp number | ||||||
1-3 | 106 | 30 (28.3) | 36 (34.0) | 1.149 | 0.582-2.270 | 0.688 |
4-9 | 46 | 12 (26.1) | 14 (30.4) | 1.182 | 0.477-2.929 | 0.717 |
10+ | 20 | 5 (25.0) | 9 (45.0) | 0.766 | 0.232-2.527 | 0.661 |
Adenoma size (mm) | ||||||
0-9 | 82 | 23 (28.0) | 25 (30.5) | 1.269 | 0.605-2.663 | 0.528 |
10-19 | 30 | 10 (33.3) | 9 (30.0) | 1.533 | 0.553-4.248 | 0.410 |
20+ | 16 | 1 (6.3) | 7 (43.8) | 0.197 | 0.023-1.690 | 0.140 |
Polyp location | ||||||
Rectum | 79 | 19 (24.1) | 33 (41.8) | 0.794 | 0.379-1.664 | 0.541 |
Sigmoid colon | 77 | 24 (31.2) | 22 (28.6) | 1.505 | 0.710-3.187 | 0.285 |
Descending colon | 64 | 17 (26.6) | 19 (29.7) | 1.234 | 0.549-2.775 | 0.611 |
Transverse colon | 55 | 14 (25.5) | 17 (30.9) | 1.136 | 0.484-2.668 | 0.770 |
Ascending colon | 57 | 12 (21.1) | 18 (31.6) | 0.920 | 0.384-2.201 | 0.851 |
The association of gastric intestinal metaplasia with the number of colorectal neoplasms was also impacted by the small sample size, as the OR values varied considerably. The OR value was greater than 1 when the number of polyps was between 1 and 3 or between 4 and 9, while the OR value was smaller than 1 when the number of polyps was greater than 10. There were only five patients with both gastric intestinal metaplasia and more than 10 colorectal polyps. Also affected by the small sample size, the association of gastric intestinal metaplasia with the size of colorectal neoplasms was inconsistent. Since there was only one patient with both gastric intestinal metaplasia and colorectal adenoma larger than 20 mm, the analysis result could hardly be representative. This was also the case for the association of gastric intestinal metaplasia with the location of colorectal neoplasms.
Compared to patients in the control group 1, patients in the gastric intraepithelial neoplasia group were slightly older and had a significantly higher proportion of males (P = 0.002, Table 4). The incidence rate of colorectal adenoma without HGIEN was significantly higher in the gastric intraepithelial neoplasia group than in the control group 1 (P = 0.013). Similarly, the incidence rates of colorectal adenoma with HGIEN and colorectal adenocarcinoma were also higher in the gastric intraepithelial neoplasia group. Gastric intraepithelial neoplasia was found more frequently in all other three groups (the colorectal adenoma group without HGIEN, the colorectal adenoma group with HGIEN and the colorectal adenocarcinoma group) than in the control group 2.
Parameter | Total number of patients (n = 233) | Gastric intraepithelial neoplasia | Control group 1 | OR | 95%CI | P value |
Age | 56.85 | 57.68 ± 11.24 | 56.42 ± 14.90 | - | - | - |
Male | 164 | 32 (19.5) | 48 (29.3) | 1.000 | - | - |
Female | 69 | 5 (7.2) | 36 (52.2) | 0.208 | 0.074-0.588 | 0.002 |
Control group 2 | 95 | 9 (9.5) | 40 (42.1) | 1.000 | - | - |
Adenoma without HGIEN | 92 | 21 (22.8) | 30 (32.6) | 3.111 | 1.248-7.753 | 0.013 |
Adenoma with HGIEN | 16 | 1 (6.3) | 3 (18.8) | 1.481 | 0.138-15.941 | 1.000 |
Adenocarcinoma | 27 | 5 (18.5) | 11 (40.7) | 2.020 | 0.561-7.272 | 0.306 |
Polyp number | ||||||
1-3 | 106 | 17 (16.0) | 36 (34.0) | 2.099 | 0.832-5.293 | 0.112 |
4-9 | 46 | 10 (21.7) | 14 (30.4) | 3.175 | 1.071-9.413 | 0.033 |
10+ | 20 | 3 (15.0) | 9 (45.0) | 1.481 | 0.333-6.596 | 0.689 |
Adenoma size (mm) | ||||||
0-9 | 82 | 16 (19.5) | 25 (30.5) | 2.844 | 1.092-7.410 | 0.029 |
10-19 | 30 | 4 (13.3) | 9 (30.0) | 1.975 | 0.496-7.868 | 0.444 |
20+ | 16 | 3 (18.8) | 7 (43.8) | 1.905 | 0.411-8.829 | 0.409 |
Polyp location | ||||||
Rectum | 79 | 12 (15.2) | 33 (41.8) | 1.616 | 0.607-4.304 | 0.335 |
Sigmoid colon | 77 | 16 (20.8) | 22 (28.6) | 3.232 | 1.227-8.512 | 0.015 |
Descending colon | 64 | 14 (21.9) | 19 (29.7) | 3.275 | 1.205-8.899 | 0.017 |
Transverse colon | 55 | 13 (23.6) | 17 (30.9) | 3.399 | 1.223-9.443 | 0.016 |
Ascending colon | 57 | 13 (22.8) | 18 (31.6) | 3.210 | 1.162-8.864 | 0.021 |
The association of gastric intraepithelial neoplasia with the number of colorectal neoplasia was similar to that of H. pylori-associated gastritis, as the OR values were all greater than 1. The association was the highest when the number of polyps was between 4 and 9 (OR = 3.175, 95%CI: 1.071-9.413, P = 0.033). The associations of gastric intraepithelial neoplasia with the size of colorectal neoplasia were also similar, with the association being strongest when the size of adenoma was 0-9 mm (OR = 2.844, 95%CI: 1.092-7.410, P = 0.029). Compared to that of H. pylori-associated gastritis, the association of gastric intraepithelial neoplasia with the location of colorectal neoplasms was even stronger. The association was statistically significant when the polyps were located at the sigmoid colon, descending colon, transverse colon and ascending colon.
Fourteen gastric adenocarcinoma patients were enrolled in the study (Table 5). Their average age (62.36 ± 16.31 years) was significantly higher than that of the control group 1 (56.42 ± 14.90 years). There was also a higher percentage of males in the gastric adenocarcinoma group than in the control group 1. The incidence rates of colorectal adenoma without HGIEN, colorectal adenoma with HGIEN and colorectal adenocarcinoma were higher in the gastric adenocarcinoma group than in the control group 1. However, the results were not statistically significant due to the small sample size. The incidence rate of gastric adenocarcinoma was higher in all three case groups than in the control group 2.
Parameter | Total number of patients (n = 233) | Gastric adenocarcinoma | Control group 1 | OR | 95%CI | P value |
Age | 56.85 | 62.36 ± 16.31 | 56.42 ± 14.90 | - | - | - |
Male | 164 | 10 (6.1) | 48 (29.3) | 1.000 | - | - |
Female | 69 | 4 (5.8) | 36 (52.2) | 0.533 | 0.155-1.838 | 0.314 |
Control group 2 | 95 | 5 (5.3) | 40 (42.1) | 1.000 | - | - |
Adenoma without HGIEN | 92 | 4 (4.3) | 30 (32.6) | 1.067 | 0.264-4.314 | 1.000 |
Adenoma with HGIEN | 16 | 1 (6.3) | 3 (18.8) | 2.667 | 0.231-30.800 | 0.418 |
Adenocarcinoma | 27 | 3 (11.1) | 11 (40.7) | 2.182 | 0.450-10.585 | 0.379 |
Polyp number | ||||||
1-3 | 106 | 5 (4.7) | 36 (34.0) | 1.111 | 0.297-4.155 | 1.000 |
4-9 | 46 | 1 (2.2) | 14 (30.4) | 0.571 | 0.061-5.323 | 1.000 |
10+ | 20 | 0 (0.0) | 9 (45.0) | - | - | - |
Adenoma size (mm) | ||||||
0-9 | 82 | 3 (3.7) | 25 (30.5) | 0.960 | 0.211-4.372 | 1.000 |
10-19 | 30 | 2 (6.7) | 9 (30.0) | 1.778 | 0.296-10.671 | 0.614 |
20+ | 16 | 1 (6.3) | 7 (43.8) | 1.143 | 0.115-11.311 | 1.000 |
Polyp location | ||||||
Rectum | 79 | 2 (2.5) | 33 (41.8) | 0.485 | 0.088-2.663 | 0.459 |
Sigmoid colon | 77 | 3 (3.9) | 22 (28.6) | 1.091 | 0.238-5.003 | 1.000 |
Descending colon | 64 | 1 (1.6) | 19 (29.7) | 0.421 | 0.046-3.859 | 0.657 |
Transverse colon | 55 | 1 (1.8) | 17 (30.9) | 0.471 | 0.051-4.336 | 0.664 |
Ascending colon | 57 | 3 (5.3) | 18 (31.6) | 1.333 | 0.287-6.192 | 0.702 |
The relationship of gastric adenocarcinoma with the number of colorectal neoplasia varied widely because of the small sample size. There was no patient with both gastric adenocarcinoma and more than 10 colorectal polyps in this study. Also because of the small sample size, the association of gastric adenocarcinoma with the size of colorectal neoplasms was inconsistent, leading to low reliability. It was the same situation for the association of gastric adenocarcinoma with the location of colorectal neoplasia.
The first report that H. pylori infection might be associated with colorectal neoplasia (particularly colorectal adenomas) could be traced back to 1997[10]. Several previous studies have shown a positive correlation between H. pylori infection and colorectal neoplasia in different populations, such as African American[11], German[6,8], and Israelite[12]. However, other studies did not support the idea that H. pylori infection was associated with the development of colorectal neoplasia. For example, Strofilas et al[4] found that there was no significant difference of anti-H. pylori IgG antibodies between the colorectal cancer group and the control group in Greeks. A recent meta-analysis also failed to find a statistical association between H. pylori infection and colorectal neoplasia among the East Asian population[13]. In addition, such lack of association between H. pylori and colorectal adenomas was also reported in the United States Hispanic population[14]. Therefore, it was speculated that the relationship between H. pylori infection and colorectal neoplasia was race dependent[15], making it important to analyze data based on race.
Most previous studies used positive serology as the indicator of H. pylori infection[16-19], while others used the presence of H. pylori-associated gastritis as the indicator[20-22]. Yet very few studies used other H. pylori-associated gastric diseases as indicators during the investigation of the association of colorectal neoplasia with H. pylori-associated gastric diseases as well as their severity. In particular, to our knowledge, no such study has been performed on the Chinese population. Since Chinese represent more than one fifth of the world total population, it is of great significance to investigate the relationship between H. pylori-associated gastric diseases and colorectal neoplasia in the Chinese population.
Our study demonstrated that H. pylori-associated gastric diseases might increase the risk of colorectal neoplasia regardless of the number, size and location of the neoplasm, although some results were not statistically significant as the sample size was too small. Generally we can assume that H. pylori infection as well as H. pylori-associated gastric diseases are potential risk factors for colorectal neoplasia.
Chinese population has a high prevalence of H. pylori infection and H. pylori-associated gastric diseases[23]. The incidence rate of colorectal adenocarcinoma is also high in China[24]. Early diagnosis of colorectal adenocarcinoma is relatively low even though early diagnosis is very important to lower the mortality[25]. Our research showed that people who had H. pylori-associated gastric diseases did have high risk of colorectal neoplasia. It is important to encourage patients with H. pylori-associated gastric diseases to undergo colonoscopy earlier and more frequently, to improve the early diagnostic rate of colorectal adenocarcinoma. In addition, people in the high-risk group should receive some interventions, such as lifestyle changes, which may lower the risk of developing cancer.
One advantage of this study was that RUT and histopathological results were used to determine the H. pylori infection status. As the gold standard for H. pylori infection diagnosis[26], histopathological examination can diagnose the H. pylori infection and pathologic changes of the stomach at the same time. Compared to serological tests that cannot differentiate existing infections from historical ones, RUT and histopathological tests diagnose only existing H. pylori infection. Such a distinction is vital since only existing H. pylori infection stimulates immune responses that can induce or perpetuate chronic inflammation in the gastrointestinal tract, and many malignancies are associated with epigenetic alterations induced by chronic inflammation[27,28].
How H. pylori infection increases the risk of colorectal neoplasia has not yet been elucidated. One common hypothesis is that hypergastrinemia induced by H. pylori infection contributes to the colorectal carcinogenesis, as high levels of gastrin can promote colorectal cell growth in vitro and increase colorectal cancer rates in animal models[29-31]. Since serum gastrin levels increase significantly as the healthy stomach progresses to malignancy[32], it could be inferred that the correlation between H. pylori-associated gastric diseases and colorectal neoplasia should be higher as the severity of the gastric lesions increases. However, our study showed that there was little association of the type of H. pylori-associated gastric diseases with colorectal neoplasia. This negative result might be due to the small sample size. As no gastrin level data was included in the study, it might also be because the gastrin levels were similar in different H. pylori-associated gastric diseases, as gastrin levels could be influenced by many factors. Yet other studies did show that gastrin levels were not related to colorectal neoplasia[6]. That being said, more studies are needed to clarify this issue. The relatively small sample size of our study also made it impossible to perform multivariate logistic analysis to eliminate possible confounding factors, restricting the research conclusion. Another limitation is that since all data were collected from the same center, some bias such as environmental factor might impact the results.
In conclusion, our study revealed that H. pylori infection and H. pylori-associated gastric diseases are potential risk factors of colorectal neoplasia. Early colonoscopy and interventions should be taken to reduce the risk of colorectal neoplasia for people with H. pylori-associated gastric diseases. Studies with larger sample size and multi-center data collection for Chinese population are needed to further clarify this association and to understand the underlying pathophysiological mechanism.
Colorectal cancer (CRC) is one of the most common malignancies worldwide. Colorectal adenoma is considered the most important precancerous lesion for CRC, and these two diseases are collectively called colorectal neoplasia. Accumulating evidence indicates that in addition to being a major risk factor of gastric cancer, Helicobacter pylori (H. pylori) infection is also associated with colorectal neoplasia. Although several previous studies concluded that H. pylori seropositivity was associated with colorectal neoplasia, few have investigated the relationship between H. pylori-associated gastric diseases and colorectal neoplasia. In particular, no such research on the Chinese population has been reported so far. In this study, we carried out a retrospective analysis of a database of 60501 Chinese patients who underwent esophago-gastro-duodenoscopy and/or colonoscopy, trying to explore the possible correlation between H. pylori-associated gastric diseases and colorectal neoplasia.
Early diagnosis of colorectal cancer is very important to lower the mortality. Based on these results, it is critical for patients with H. pylori-associated gastric diseases to receive colonoscopy and interventions earlier to improve prognosis.
In this study, the authors investigated the possible correlation between H. pylori-associated gastric diseases and colorectal neoplasia in the Chinese population for the first time. Since the relationship between H. pylori infection and colorectal neoplasia was considered race dependent, these results supplemented the hypothesis that H. pylori-associated gastric diseases are potential risk factors of colorectal neoplasia with evidence from the Chinese population.
These results suggest that H. pylori infection and H. pylori-associated gastric diseases are potential risk factors of colorectal neoplasia, encouraging people in the high-risk group to receive colonoscopy and some interventions earlier and more frequently, thus improve the early diagnostic rate of colorectal adenocarcinoma.
It is an interesting study, but includes too few subjects to have such a conclusion. It is in the text that H. pylori infection may affect colorectal neoplasm formation differently in different races. And this study reported for the first time how H. pylori-associated gastric diseases are correlated with colorectal neoplasm in the Chinese people, representing its innovation.
P- Reviewer: Furka A, Kleeff J, Perea J S- Editor: Ma YJ L- Editor: Wang TQ E- Editor: Ma S
1. | Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115-132. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 11444] [Cited by in F6Publishing: 12761] [Article Influence: 1595.1] [Reference Citation Analysis (2)] |
2. | Hong SN, Lee SM, Kim JH, Lee TY, Kim JH, Choe WH, Lee SY, Cheon YK, Sung IK, Park HS. Helicobacter pylori infection increases the risk of colorectal adenomas: cross-sectional study and meta-analysis. Dig Dis Sci. 2012;57:2184-2194. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 40] [Cited by in F6Publishing: 50] [Article Influence: 4.2] [Reference Citation Analysis (0)] |
3. | Wang F, Sun MY, Shi SL, Lv ZS. Helicobacter pylori infection and normal colorectal mucosa-adenomatous polyp-adenocarcinoma sequence: a meta-analysis of 27 case-control studies. Colorectal Dis. 2014;16:246-252. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis (0)] |
4. | Strofilas A, Lagoudianakis EE, Seretis C, Pappas A, Koronakis N, Keramidaris D, Koukoutsis I, Chrysikos I, Manouras I, Manouras A. Association of helicobacter pylori infection and colon cancer. J Clin Med Res. 2012;4:172-176. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 15] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis (0)] |
5. | Georgopoulos SD, Polymeros D, Triantafyllou K, Spiliadi C, Mentis A, Karamanolis DG, Ladas SD. Hypergastrinemia is associated with increased risk of distal colon adenomas. Digestion. 2006;74:42-46. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 63] [Cited by in F6Publishing: 68] [Article Influence: 4.0] [Reference Citation Analysis (0)] |
6. | Selgrad M, Bornschein J, Kandulski A, Hille C, Weigt J, Roessner A, Wex T, Malfertheiner P. Helicobacter pylori but not gastrin is associated with the development of colonic neoplasms. Int J Cancer. 2014;135:1127-1131. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 4.6] [Reference Citation Analysis (0)] |
7. | Wu Q, Yang ZP, Xu P, Gao LC, Fan DM. Association between Helicobacter pylori infection and the risk of colorectal neoplasia: a systematic review and meta-analysis. Colorectal Dis. 2013;15:e352-e364. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 5.2] [Reference Citation Analysis (0)] |
8. | Zhang Y, Hoffmeister M, Weck MN, Chang-Claude J, Brenner H. Helicobacter pylori infection and colorectal cancer risk: evidence from a large population-based case-control study in Germany. Am J Epidemiol. 2012;175:441-450. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 71] [Cited by in F6Publishing: 81] [Article Influence: 6.8] [Reference Citation Analysis (0)] |
9. | Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996;20:1161-1181. [PubMed] [Cited in This Article: ] |
10. | Meucci G, Tatarella M, Vecchi M, Ranzi ML, Biguzzi E, Beccari G, Clerici E, de Franchis R. High prevalence of Helicobacter pylori infection in patients with colonic adenomas and carcinomas. J Clin Gastroenterol. 1997;25:605-607. [PubMed] [Cited in This Article: ] |
11. | Brim H, Zahaf M, Laiyemo AO, Nouraie M, Pérez-Pérez GI, Smoot DT, Lee E, Razjouyan H, Ashktorab H. Gastric Helicobacter pylori infection associates with an increased risk of colorectal polyps in African Americans. BMC Cancer. 2014;14:296. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis (0)] |
12. | Shmuely H, Melzer E, Braverman M, Domniz N, Yahav J. Helicobacter pylori infection is associated with advanced colorectal neoplasia. Scand J Gastroenterol. 2014;49:35-42. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis (0)] |
13. | Guo Y, Li HY. Association between Helicobacter pylori infection and colorectal neoplasm risk: a meta-analysis based on East Asian population. J Cancer Res Ther. 2014;10 Suppl:263-266. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis (0)] |
14. | Patel S, Lipka S, Shen H, Barnowsky A, Silpe J, Mosdale J, Pan Q, Fridlyand S, Bhavsar A, Abraham A. The association of H. pylori and colorectal adenoma: does it exist in the US Hispanic population? J Gastrointest Oncol. 2014;5:463-468. [PubMed] [DOI] [Cited in This Article: ] [Cited by in F6Publishing: 14] [Reference Citation Analysis (0)] |
15. | Venerito M, Vasapolli R, Rokkas T, Malfertheiner P. Helicobacter pylori and Gastrointestinal Malignancies. Helicobacter. 2015;20 Suppl 1:36-39. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis (0)] |
16. | Engin AB, Karahalil B, Karakaya AE, Engin A. Helicobacter pylori and serum kynurenine-tryptophan ratio in patients with colorectal cancer. World J Gastroenterol. 2015;21:3636-3643. [PubMed] [DOI] [Cited in This Article: ] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 43] [Article Influence: 4.8] [Reference Citation Analysis (0)] |
17. | Venerito M, Selgrad M, Malfertheiner P. Helicobacter pylori: gastric cancer and extragastric malignancies - clinical aspects. Helicobacter. 2013;18 Suppl 1:39-43. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis (0)] |
18. | Cheng H, Zhang T, Gu W, Shu X, Zhang Y, Zhang X, Wu X, Chen J, Jiang M. The presence of Helicobacter pylori in colorectal polyps detected by immunohistochemical methods in children. Pediatr Infect Dis J. 2012;31:364-367. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis (0)] |
19. | Engin AB, Karahalil B, Engin A, Karakaya AE. Oxidative stress, Helicobacter pylori, and OGG1 Ser326Cys, XPC Lys939Gln, and XPD Lys751Gln polymorphisms in a Turkish population with colorectal carcinoma. Genet Test Mol Biomarkers. 2010;14:559-564. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 38] [Cited by in F6Publishing: 43] [Article Influence: 3.1] [Reference Citation Analysis (0)] |
20. | Inoue I, Kato J, Tamai H, Iguchi M, Maekita T, Yoshimura N, Ichinose M. Helicobacter pylori-related chronic gastritis as a risk factor for colonic neoplasms. World J Gastroenterol. 2014;20:1485-1492. [PubMed] [DOI] [Cited in This Article: ] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis (0)] |
21. | Bae RC, Jeon SW, Cho HJ, Jung MK, Kweon YO, Kim SK. Gastric dysplasia may be an independent risk factor of an advanced colorectal neoplasm. World J Gastroenterol. 2009;15:5722-5726. [PubMed] [DOI] [Cited in This Article: ] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis (0)] |
22. | Inoue I, Mukoubayashi C, Yoshimura N, Niwa T, Deguchi H, Watanabe M, Enomoto S, Maekita T, Ueda K, Iguchi M. Elevated risk of colorectal adenoma with Helicobacter pylori-related chronic gastritis: a population-based case-control study. Int J Cancer. 2011;129:2704-2711. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 45] [Cited by in F6Publishing: 52] [Article Influence: 4.0] [Reference Citation Analysis (0)] |
23. | Wang CH, Liao ST, Yang J, Li CX, Yang YY, Han R, Chen DF, Lan CH. Effects of daily telephone-based re-education before taking medicine on Helicobacter pylori eradication: A prospective single-center study from China. World J Gastroenterol. 2015;21:11179-11184. [PubMed] [DOI] [Cited in This Article: ] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis (0)] |
24. | Zheng R, Zeng H, Zhang S, Chen T, Chen W. National estimates of cancer prevalence in China, 2011. Cancer Lett. 2016;370:33-38. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 117] [Cited by in F6Publishing: 143] [Article Influence: 15.9] [Reference Citation Analysis (0)] |
25. | Li L, Guo Y, Chen Y, Wang J, Zhen L, Guo X, Liu J, Jing C. The Diagnostic Efficacy and Biological Effects of microRNA-29b for Colon Cancer. Technol Cancer Res Treat. 2015;Epub ahead of print. [PubMed] [Cited in This Article: ] |
26. | El-Zimaity H, Serra S, Szentgyorgyi E, Vajpeyi R, Samani A. Gastric biopsies: the gap between evidence-based medicine and daily practice in the management of gastric Helicobacter pylori infection. Can J Gastroenterol. 2013;27:e25-e30. [PubMed] [Cited in This Article: ] |
27. | Kountouras J, Kapetanakis N, Zavos C, Polyzos SA, Kouklakis G, Venizelos I, Nikolaidou C, Tzilves D, Paikos D, Katsinelos P. Active Helicobacter pylori infection is associated with colorectal mucosa-adenomatous polyp--early and advanced adenocarcinoma sequence. Scand J Gastroenterol. 2014;49:381-382. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis (0)] |
28. | Pilpilidis I, Kountouras J, Zavos C, Katsinelos P. Upper gastrointestinal carcinogenesis: H. pylori and stem cell cross-talk. J Surg Res. 2011;166:255-264. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis (0)] |
29. | Han YM, Park JM, Kangwan N, Jeong M, Lee S, Cho JY, Ko WJ, Hahm KB. Role of proton pump inhibitors in preventing hypergastrinemia-associated carcinogenesis and in antagonizing the trophic effect of gastrin. J Physiol Pharmacol. 2015;66:159-167. [PubMed] [Cited in This Article: ] |
30. | Chueca E, Lanas A, Piazuelo E. Role of gastrin-peptides in Barrett’s and colorectal carcinogenesis. World J Gastroenterol. 2012;18:6560-6570. [PubMed] [DOI] [Cited in This Article: ] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis (0)] |
31. | Singh P, Sarkar S, Kantara C, Maxwell C. Progastrin Peptides Increase the Risk of Developing Colonic Tumors: Impact on Colonic Stem Cells. Curr Colorectal Cancer Rep. 2012;8:277-289. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis (0)] |
32. | Sun L, Tu H, Liu J, Gong Y, Xu Q, Jing J, Dong N, Yuan Y. A comprehensive evaluation of fasting serum gastrin-17 as a predictor of diseased stomach in Chinese population. Scand J Gastroenterol. 2014;49:1164-1172. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis (0)] |